Lamivudine

IUPAC Name: 4-amino-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one 
Empirical Formula: C₈H₁₁N₃O₃S
Molecular Weight: 229.2562g/mol
Structure of Lamivudine (CAS NO.134678-17-4):

Index of Refraction: 1.754
Molar Refractivity: 54.14 cm³
Molar Volume: 132.2 cm³
Polarizability: 21.46×10^-24cm3
Surface Tension: 79.3 dyne/cm
Density: 1.73 g/cm3
Flash Point: 241.3 °C
Enthalpy of Vaporization: 85.17 kJ/mol 
Melting Point: 177 °C
Boiling Point: 475.4 °C at 760 mmHg
Vapour Pressure: 4.91E-11 mmHg at 25°C 
Product Categories: Active Pharmaceutical Ingredients;Antivirals for Research and Experimental Use;Biochemistry;Chemical Reagents for Pharmacology Research;Nucleosides and their analogs;Nucleosides, Nucleotides & Related Reagents;Anti-virals;Intermediates & Fine Chemicals;Pharmaceuticals;API's 
Canonical SMILES: C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Isomeric SMILES: C1[C@@H](O[C@@H](S1)CO)N2C=CC(=NC2=O)N
InChI: InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m1/s1
InChIKey: JTEGQNOMFQHVDC-RQJHMYQMSA-N

 Lamivudine (CAS NO.134678-17-4) was produce by Bernard Belleau while at work at Nghe Nguyen-Ga and McGill University at the Montreal-based IAF BioChem International, Inc. laboratories in 1989. Initially designed as an antiviral agent, the drug's effectiveness for treating HIV in combination with AZT was discovered by Yung-Chi (Tommy) Cheng at Yale University. The drug was later licensed to the British pharmaceutical company Glaxo for a 14 percent royalty.
 Lamivudine (CAS NO.134678-17-4) was approved by the Food and Drug Administration (FDA) on November 17, 1995 for use with zidovudine (AZT) and again in 2002 as a once-a-day dosed medication. The fifth antiretroviral drug on the market, it was the last NRTI for three years while the approval process switched to protease inhibitors. According to the manufacturer's 2004 annual report, its patent will expireand in Europe in 2011 and in the United States in 2010 .

 Lamivudine has been used for treatment of chronic hepatitis B at a lower dose than for treatment of HIV. It improves the seroconversion of e-antigen positive hepatitis B and also improves histology staging of the liver. Long term use of lamivudine unfortunately leads to emergence of a resistant hepatitis B virus (YMDD) mutant. Despite this, lamivudine is still used widely as it is well tolerated.

Oral Toxicity: Not expected to be toxic following ingestion.
Inhalation Toxicity: No studies have been conducted.

RTECS: UW7361333
Hazardous Substances Data: 134678-17-4(Hazardous Substances Data)

APPEARANCE: White to off-white crystalline powder
ASSAY: 98.0 - 102.0%
RESIDUE ON IGNITION: 0.25% max
LOSS ON DRYING: 0.5% max
OPTICAL ROTATION: -93^° ~ -100^°
HEAVY METALS: 20 ppm max

  Lamivudine , its cas register number is 134678-17-4. It also can be called (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine ; (-)-2'-Deoxy-3'-thiacytidine ; 3'-Thia-2',3'-dideoxycytidine ; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone ; Epivir ; Epivir-HBV ; GR 109714X ; HSDB 7155 ; Hepitec ;
 Heptovir ; Lamivudine ; UNII-2T8Q726O95 ; Zeffix ; beta-L-2',3'-Dideoxy-3'-thiacytidine ; beta-L-3'-Thia-2',3'-dideoxycytidine . Lamivudine (CAS NO.134678-17-4) is a white crystalline powder.